Drug
NLRP3 Inhibitor DFV890 clinical trials
Also written DFV890.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses NLRP3 Inhibitor DFV890 is read from its arms, and is right about nine times in ten.
Testing it · 6
- Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesActive, not recruitingPhase 1Novartis PharmaceuticalsNCT05552469Written as DFV890
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRPCompletedPhase 2Novartis PharmaceuticalsNCT06031844Written as DFV890
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)CompletedPhase 2Novartis PharmaceuticalsNCT06097663Written as DFV890
- Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee OsteoarthritisCompletedPhase 2Novartis PharmaceuticalsNCT04886258Written as DFV890
- Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)CompletedPhase 2Novartis PharmaceuticalsNCT04868968Written as DFV890
- Study of Efficacy and Safety of DV890 in Patients With COVID-19 PneumoniaCompletedPhase 2Novartis PharmaceuticalsNCT04382053Written as DFV890